Review Article
Multimodal Liver-Directed Management of Neuroendocrine Hepatic Metastases
Table 3
Summary of outcomes for intraarterial therapy of neuroendocrine liver metastases. HAE: hepatic artery embolization; HACE: hepatic artery chemoembolization; HAI: hepatic artery infusion; OS: overall survival.
| First author, publication year | No. of embolized patients | Survival data | Comments |
| Paprottka, 2011 [50] | 42 [90Y radio-embolization] | 40 of 42 patients alive with mean followup of 16.2 months | 36 of 38 symptomatic patients had clinical improvement within 3 months | Dong, 2010 [51] | 123 [HACE] | Mean OS: 39.6 months 5-year OS: 36% 10-year OS: 20% | Baseline albumin <3.5 g/dL was a multivariate predictor for poorer OS () | Kennedy, 2008 [52] | 148 [90Y radio-embolization] | Median OS: 70 months | No radiation-induced liver disease or failure, even with retreatment | Christante, 2008 [49] | 77 [18 HAI alone, 59 HAI + HACE] | Median OS [HAI alone]: 26 months Median OS [HAI + HACE]: 39 months | All 10 patients with nonfunctional neoplasms and 15 of 16 patients with islet cell neoplasms died within 5 years | Strosberg, 2006 [53] | 84 [HAE] | Median OS: 36 months | Fewer symptoms in 44 of 55 patients | Gupta, 2005 [54] | 123 [74 HAE, 49 HACE] | Median OS [carcinoid]: 33.8 months Median OS [islet cell]: 23.2 months | Male gender predicted worse OS () for carcinoid, bone mets predicted worse OS for islet cell () |
|
|